11.10.25 -- STREAM Edition: Supply Chain Due Diligence Before Acquiring Bio Assets

As AAV vectors remain the most prominent technology in the gene therapy space, key players have established platform processes that can enable faster, more consistent development and scaleup. Crucial components are pre-stocked, ready-to-use transient transfection plasmids termed as off-the-shelf (OTS) plasmids. OTS plasmids can expedite timelines and simplify supply chains, enabling a fully integrated offering that allows for rapid progression into AAV process development. Learn more now.

Watch Senior Director of Bioassay Erika Kovacs discuss critical considerations for developing stage-appropriate bioassays to support complex biologics and bioconjugates on the path to IND.

Selecting a container closure system for a sterile injectable can be daunting. Gain confidence in what you're choosing by using this data-driven approach to predicting and verifying container closure integrity.

Join Dr. Srinivasan Shanmugam in this insightful webinar to learn key strategies for selecting the right CDMO, reducing costs, accelerating timelines, and ensuring product success.

Before an organization decides to acquire or in-license an asset for development, it's key to evaluate the chain of events and partners that progressed that asset to the point it is now at.

With decades of experience, we offer a flexible and collaborative partnership model for manufacturing excellence that enables our clients to increase speed to market with full regulatory confidence.

Discover optimized AAV production with polyethylenimine (PEI) and non-polyethylenimine transfection solutions that are designed to boost titers and streamline scalability.